About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Phosphagenics Appoints Three New Directors

April 13, 2015

click here to read more

Post navigation

Phosphagenics signs license agreement to expand TPM®-based animal nutrition products to the UK and Ireland

Phosphagenics Initiates Oxycodone Patch Dosing in Phase 2 Clinical Trial

Related Posts

Investor Presentation April 2018

April 17, 2018

Phosphagenics Participation in ‘New Innovations in Drug Delivery Technology’ Webcast

April 12, 2017

Avecho commences CBD softgel manufacturing for pivotal Phase III insomnia study

May 17, 2023May 17, 2023

Recent Posts

First Patient Dosed in Phase III Insomnia Trial
May 16, 2024
MEDIA | Channel 9 News
March 28, 2024
Avecho’s Phase III Clinical Trial for Insomnia Commences
March 26, 2024

Categories

Analyst Coverage
Company Announcement
Company Report
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.